Telesis Bio Raises $21M to Spark Next-Generation Synthetic Biology Breakthroughs

Telesis Bio is thrilled to announce its recent funding milestone, having successfully raised $21 million to further propel advancements in synthetic biology. This funding round highlights the immense confidence investors have in Telesis Bio’s innovative approach to tackling some of humanity’s greatest challenges. As a company at the forefront of scientific innovation, Telesis Bio is dedicated to empowering researchers with breakthrough automation solutions for biological synthesis. Their cutting-edge expertise in DNA biology allows them to revolutionize the rapid, accurate, and reproducible writing of DNA and mRNA, opening new frontiers across diverse biological applications. The new capital will be strategically employed to accelerate ongoing research and development efforts, optimizing automation technologies to overcome existing bottlenecks in synthetic biology workflows. With a focus on fostering robust collaborations, Telesis Bio is already partnering with premier academic institutions, emerging startups, and nearly all of the Top 25 biopharma companies. These partnerships are instrumental in driving pioneering advances—from developing novel infectious disease vaccines and precision immunotherapies for cancer to engineering innovative antibody therapeutics, sustainable cellular agricultural products, and even engineered meat substitutes. This injection of funds not only cements Telesis Bio’s role as a trusted leader in synthetic biology but also fuels the company’s mission to enhance the capabilities of researchers worldwide. By expanding its technological portfolio and scaling its operations, Telesis Bio is poised to make significant contributions to both fundamental research and transformative healthcare solutions, setting a new benchmark for innovation and collaboration in the industry.